We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2)

This study is currently recruiting participants.
Verified October 2017 by QuantumLeap Healthcare Collaborative
Sponsor:
ClinicalTrials.gov Identifier:
NCT01042379
First Posted: January 5, 2010
Last Update Posted: October 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
QuantumLeap Healthcare Collaborative
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Study Completion Date: No date given
  Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):